Millennium Management LLC Sells 143,334 Shares of Immuneering Co. (NASDAQ:IMRX)

Millennium Management LLC cut its stake in shares of Immuneering Co. (NASDAQ:IMRX - Free Report) by 58.2% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 102,936 shares of the company's stock after selling 143,334 shares during the quarter. Millennium Management LLC owned approximately 0.33% of Immuneering worth $226,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the stock. First Manhattan CO. LLC. bought a new stake in Immuneering during the 4th quarter worth about $71,000. Bridgeway Capital Management LLC raised its stake in shares of Immuneering by 77.4% during the 4th quarter. Bridgeway Capital Management LLC now owns 51,349 shares of the company's stock worth $113,000 after purchasing an additional 22,400 shares in the last quarter. Marshall Wace LLP bought a new stake in shares of Immuneering during the 4th quarter worth approximately $47,000. XTX Topco Ltd raised its stake in Immuneering by 177.2% in the 4th quarter. XTX Topco Ltd now owns 32,650 shares of the company's stock valued at $72,000 after acquiring an additional 20,871 shares during the period. Finally, Rockefeller Capital Management L.P. acquired a new position in Immuneering in the 4th quarter valued at $390,000. 67.65% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Several research firms have recently issued reports on IMRX. Oppenheimer reduced their target price on Immuneering from $25.00 to $21.00 and set an "outperform" rating on the stock in a report on Wednesday, May 7th. Needham & Company LLC reiterated a "buy" rating and issued a $9.00 target price on shares of Immuneering in a report on Thursday, June 5th. Finally, Chardan Capital restated a "buy" rating and set a $13.00 price objective on shares of Immuneering in a report on Tuesday, May 6th.

Immuneering Stock Down 3.1%

IMRX stock traded down $0.06 during midday trading on Friday, hitting $1.90. The company's stock had a trading volume of 175,598 shares, compared to its average volume of 2,355,100. The stock has a market cap of $68.37 million, a price-to-earnings ratio of -0.96 and a beta of 0.01. The stock's 50-day moving average price is $1.50 and its 200 day moving average price is $1.74. Immuneering Co. has a 1 year low of $1.00 and a 1 year high of $3.83.

Immuneering (NASDAQ:IMRX - Get Free Report) last issued its earnings results on Monday, May 5th. The company reported ($0.42) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.41) by ($0.01). As a group, equities analysts forecast that Immuneering Co. will post -1.86 earnings per share for the current fiscal year.

Immuneering Company Profile

Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 is in Investigational New Drug application to treat solid tumors.